Digest Network Come funziona
Network
/
Società
Ki
Non verificato

Kiromic BioPharma, Inc.

Di cosa scriviamo

FarmaceuticaIndustriaMedicina - VarieOncologiaSalute

12 comunicati stampa

Guarda tutti i comunicati
18/02/2025
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Kiromic BioPharma Reports Patient 4 in Deltacel-01 Clinical Trial Reaches 10-Month Progression-Free Survival
Fonte
Kiromic BioPharma, Inc.
Emittente
Business Wire
1.00
0
21/01/2025
Industria
Salute
Tecnica
Medicina - Varie
Oncologia
Kiromic BioPharma Reports Tumor Volume Decrease in Two Patients Enrolled in Deltacel-01
Fonte
Kiromic BioPharma, Inc.
Emittente
Business Wire
1.00
0
12/12/2024
Salute
Oncologia
Medicina - Varie
Industria
Kiromic BioPharma Reports 32% Decrease in Tumor Volume Eight Months Post-Treatment in Fourth Patient Enrolled in Deltacel-01
Fonte
Kiromic BioPharma, Inc.
Emittente
Business Wire
1.00
0
03/12/2024
Biotecnologia
Farmaceutica
Salute
Oncologia
Kiromic BioPharma Announces Settlement of Previously Disclosed SEC Investigation
Fonte
Kiromic BioPharma, Inc.
Emittente
Business Wire
1.00
0
08/10/2024
Industria
Oncologia
Salute
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
Kiromic BioPharma Reports Favorable Ongoing Clinical Results From Fourth and Sixth Patients Enrolled in Deltacel-01
Fonte
Kiromic BioPharma, Inc.
Emittente
Business Wire
1.00
0
01/10/2024
Industria
Sanità
Salute
Medicina - Varie
Oncologia
Kiromic BioPharma Reports Favorable 10-Month Follow-Up Results for the First Patient Treated in its Deltacel-01 Clinical Trial
Fonte
Kiromic BioPharma, Inc.
Emittente
Business Wire
1.00
0
19/09/2024
Industria
Oncologia
Salute
Scienza
Farmaceutica
Biotecnologia
Kiromic BioPharma Activates the University of Arizona Cancer Center as the Fifth Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial
Fonte
Kiromic BioPharma, Inc.
Emittente
Business Wire
1.00
0
19/09/2024
Industria
Biotecnologia
Farmaceutica
Oncologia
Sanità
Salute
Medicina - Varie
Kiromic BioPharma Advances Deltacel-01 Into Expansion Phase Following Safety Monitoring Committee’s Unanimous Recommendation
Fonte
Kiromic BioPharma, Inc.
Emittente
Business Wire
1.00
0
14/08/2024
Scienza
Farmaceutica
Oncologia
Tecnica
Medicina - Varie
Biotecnologia
Igiene alimentare
Salute
Industria
Kiromic BioPharma’s Deltacel Receives FDA Fast Track Designation
Fonte
Kiromic BioPharma, Inc.
Emittente
Business Wire
1.00
0
09/08/2024
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Industria
Kiromic BioPharma Provides Update on Part 1 of the Deltacel-01 Trial
Fonte
Kiromic BioPharma, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0